Back to today’s briefing

Story perspectives

Novo Nordisk's 20.7% Weight Loss Triumph Faces Stock Setback

1/21/2025

36 6

Summary

Story summary

Novo Nordisk's groundbreaking STEP UP trial showcased the power of a 7.2 mg dose of semaglutide, achieving an impressive 20.7% weight loss in obese patients over 72 weeks, far surpassing the 2.4 mg dose and placebo. However, despite these remarkable results, the company's stock took a hit, facing stiff competition from Eli Lilly's Zepbound and looming Medicare price negotiations.

1 of 1

Story summary

Novo Nordisk's groundbreaking STEP UP trial showcased the power of a 7.2 mg dose of semaglutide, achieving an impressive 20.7% weight loss in obese patients over 72 weeks, far surpassing the 2.4 mg dose and placebo. However, despite these remarkable results, the company's stock took a hit, facing stiff competition from Eli Lilly's Zepbound and looming Medicare price negotiations.